Page last updated: 2024-12-06
1-methylhypoxanthine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
1-methylhypoxanthine is a naturally occurring purine derivative found in various organisms. It is a structural analog of hypoxanthine, a crucial component of DNA and RNA. 1-methylhypoxanthine is known to exhibit biological activity, including potential roles in cell signaling and regulation. Research suggests it may be involved in processes such as neurotransmission, immune responses, and even cancer development. Its synthesis and metabolism are interconnected with cellular pathways involving purine biosynthesis and degradation. Researchers study 1-methylhypoxanthine to understand its precise mechanisms of action, its potential therapeutic applications, and its contributions to various physiological processes.'
1-methylhypoxanthine: increased concentration in rats bearing Yoshida Tumour [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
1-methylhypoxanthine : A methylhypoxanthine that is hypoxanthine with the methyl group at position 1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 70765 |
| CHEMBL ID | 1868124 |
| CHEBI ID | 73959 |
| SCHEMBL ID | 2115745 |
| SCHEMBL ID | 1992699 |
| MeSH ID | M0086170 |
Synonyms (43)
| Synonym |
|---|
| smr001557673 |
| 1-methylhypoxanthine |
| hypoxanthine, 1-methyl- |
| 1125-39-9 |
| nsc57902 |
| nsc-57902 |
| mls002667916 , |
| 4(3h)-quinazolinone, 2-(methylthio)- |
| inchi=1/c6h6n4o/c1-10-3-9-5-4(6(10)11)7-2-8-5/h2-3h,1h3,(h,7,8 |
| 1-methyl-1,9-dihydro-purin-6-one |
| 1-methyl-7h-purin-6-one |
| 1-methyl-1,9-dihydro-6h-purin-6-one |
| NCGC00246838-01 |
| 1-methyl-1h-purin-6(9h)-one |
| unii-lx5wq7jfr5 |
| 6h-purin-6-one, 1,7-dihydro-1-methyl- |
| lx5wq7jfr5 , |
| nsc 57902 |
| SCHEMBL2115745 |
| AKOS005224355 |
| 6h-purin-6-one,1,9-dihydro-1-methyl- |
| 1-methyl-1,7-dihydro-6h-purin-6-one |
| 1-methyl-hypoxanthine |
| CHEBI:73959 |
| 1,7-dihydro-1-methyl-6h-purin-6-one |
| SCHEMBL1992699 |
| 1-methyl-1,7-dihydro-6h-purin-6-one # |
| KIQMCGMHGVXDFW-UHFFFAOYSA-N |
| CHEMBL1868124 |
| DTXSID00150074 |
| 1-methyl-6,7-dihydro-1h-purin-6-one |
| 1-methylhypoxanthin |
| 1-methyl-1,9-dihydro-6h-purin-6-one (acd/name 4.0) |
| 6h-purin-6-one, 1,7-dihydro-1-methyl- (9ci) |
| hypoxanthine, 1-methyl- (8ci) |
| 2-(methylthio)-4(3h)-quinazolinone |
| 1-methyl-6,9-dihydro-1h-purin-6-one |
| Q161649 |
| 6h-purin-6-one, 1,9-dihydro-1-methyl- |
| 1,9-dihydro-1-methyl-6h-purin-6-one |
| STL439819 |
| BS-51735 |
| E84444 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (2)
| Role | Description |
|---|---|
| human urinary metabolite | Any metabolite (endogenous or exogenous) found in human urine samples. |
| rat metabolite | Any mammalian metabolite produced during a metabolic reaction in rat (Rattus norvegicus). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| methylhypoxanthine | An oxopurine that is hypoxanthine with at least one methyl group substituted on to the ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (3)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 125.8920 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 11.2202 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (5)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Molecular Functions (2)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (1)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (11)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.74
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.74) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||